Budget impact of Adrabetadex
1 evidence topic · 11 sources
Summary: eligible population, comparator prices, and absence of a published price
No budget impact model of adrabetadex (Lembaz) has been published, and no list price had been announced at approval; trade press reporting on the approval states that “List pricing for the new product has not yet been announced”.
- Eligible population: Beren Therapeutics states that approximately half of those living with NPC in the U.S., or 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the U.S. remain undiagnosed. A United States database analysis identified 294 individuals with an NPC diagnosis among 308 million unique individuals (0.95 per million) and estimated 943 prevalent cases of NPC, or 2.9 cases per million people. The developer of arimoclomol estimates approximately 900 individuals with NPC in the United States, of whom approximately 300 to 350 have been diagnosed. In manufacturer filings with California, the estimated number of patients was 300 for Miplyffa (arimoclomol) and 200 for Aqneursa (levacetylleucine). Over the year from 4/1/24 to 3/31/25, 8 Oregon Health Plan members had a diagnosis indicating NPC in their medical claims.
- Comparator prices: the ICER Launch Price and Access Report (2026) gives an annual list price of $967,432.50 and a best annual net price estimate of $940,586.25 for Miplyffa, and an annual list price of $701,321.42 and a best annual net price estimate of $576,661.54 for Aqneursa. The wholesale acquisition cost of Miplyffa reported to Texas for 1 January 2026 was $40,185 to $106,020 across the 47 mg to 124 mg strengths, and that reported for Aqneursa was $14,526. An Oklahoma Medicaid review gives $691,718.40 per year for Aqneursa at the FDA approved maximum dose of 4 g per day.